Everything below concerns 冻干制剂. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | 31 amino acids |
| Backbone modification | Aib at position 8 | Blocks DPP-4 cleavage |
| Fatty acid chain | C18 diacid | Supports albumin binding |
| Native half-life | 1 to 2 minutes | Endogenous GLP-1 |
| Analog half-life | Approximately one week | Extended by albumin binding |
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
纯度评价多采用反相高效液相色谱，流动相常加入三氟乙酸或甲酸作为离子对改性剂，检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱，实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成，用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
However, they sometimes have open borders with other non-member states through special international agreements – such as between Schengen Agreement countries as mentioned above. Presently, open border agreements of various types are in force in several areas around the world, as outlined below:
Actin, alpha 1 Actinin, alpha 1 Adaptor-related protein complex 2, alpha 1 Aldehyde dehydrogenase 3 family, member A1 Aldehyde dehydrogenase 4 family, member A1 Aldehyde dehydrogenase 5 family, member A1 Aldehyde dehydrogenase 6 family, member A1 Aldehyde dehydrogenase 9 family, member A1 Aldehyde dehydrogenase 18 family, member A1 Aldo-keto reductase family 1, member A1 Alpha-1-microglobulin/bikunin precursor Apolipoprotein A1 and ApoA-1 Milano ATPase, H+ transporting, lysosomal V0 subunit a1 ATPase, Na+/K+ transporting, alpha 1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha 1 BCL2-related protein A1 Butyrophilin, subfamily 1, member A1 Butyrophilin, subfamily 3, member A1 Capping protein (actin filament) muscle Z-line, alpha 1 Carboxypeptidase A1 Casein kinase 1, alpha 1 Casein kinase 2, alpha 1 Catenin (cadherin-associated protein), alpha 1 Centaurin, alpha 1 Cholinergic receptor, nicotinic, alpha 1 Coagulation factor XIII, A1 polypeptide collagen, type I, alpha 1 collagen, type II, alpha 1 Collagen, type III, alpha 1 Collagen, type IV, alpha 1 Collagen, type V, alpha 1 Collagen, type VI, alpha 1 Collagen, type VII, alpha 1 Collagen, type VIII, alpha 1 Collagen, type IX, alpha 1 Collagen, type X, alpha 1 Collagen, type XI, alpha 1 Collagen, type XII, alpha 1 Collagen, type XIII, alpha 1 Collagen, type XIV, alpha 1 Collagen, type XV, alpha 1 Collagen, type XVI, alpha 1 Collagen, type XVII, alpha 1 Collagen, type XVIII, alpha 1 Collagen, type XIX, alpha 1 Collagen, type XXV, alpha 1 Collagen, type XXVII, alpha 1 Crystallin, beta A1 Cyclic nucleotide-gated channel alpha 1 Cyclin A1 Cytochrome P450, family 1, member A1 Defensin, alpha 1 Dystrophin-associated protein A1 Ephrin A1 Eukaryotic translation elongation factor 1 alpha 1 Family with sequence similarity 13, member A1 Family with sequence similarity 19 (chemokine (C-C motif)-like), member A1 Gamma-aminobutyric acid (GABA) A receptor, alpha 1 Gap junction protein, alpha 1 GDNF family receptor alpha 1 Glutathione S-transferase A1 Glycine receptor, alpha 1 Heat shock protein 90kDa alpha (cytosolic), member A1 Hemoglobin, alpha 1 Heterogeneous nuclear ribonucleoprotein A1 Homeobox A1 Immunoglobulin heavy constant alpha 1 Importin alpha 1 Interferon, alpha 1 Interleukin 13 receptor, alpha 1 Karyopherin alpha 1 Laminin, alpha 1 Major histocompatibility complex, class II, DP alpha 1 Major histocompatibility complex, class II, DQ alpha 1 Myosin light chain A1, an actin-binding protein NADH dehydrogenase (ubiquinone), alpha 1 Nucleolar protein, member A1 PCDHA4 Phospholipase A1 Phosphorylase kinase, alpha 1 Plexin A1 Polymerase (DNA directed), alpha 1 Potassium large conductance calcium-activated channel, subfamily M, alpha 1 Proteasome (prosome, macropain) subunit, alpha 1 Protein kinase, AMP-activated, alpha 1 Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1 Protocadherin alpha 1 Pulmonary surfactant-associated protein A1 Pyruvate dehydrogenase (lipoamide) alpha 1 RNA binding motif protein, Y-linked, family 1, member A1 Replication protein A1 S100 calcium binding protein A1 Sec61 alpha 1 Serum amyloid A1 Solute carrier family 35 (CMP-sialic acid transporter), member A1 Spectrin, alpha 1 Sperm protein associated with the nucleus, X-linked, family member A1 Syntrophin, alpha 1 Transient receptor potential cation channel, member A1 UDP glucuronosyltransferase 1 family, polypeptide A1 Urea Transporter A1 a gene found in the maize encoding for the dihydroflavonol 4-reductase (reducing dihydroflavonols into flavan-4-ols) in the phlobaphene metabolic pathway proteins
S-Methylcysteine sulfoxide is an organosulfur compound with the formula CH3S(O)CH2CH(NH2)CO2H. It is the sulfoxide of S-methylcysteine. It contributes to the flavor of onions (Allium sp.). The compound is usually encountered as one diastereoisomer, the (R)- and (S)-configurations at the carbon and sulfur stereocenters, respectively. The S-methyl part of the name refers to the location of the methyl group on sulfur. Although odorless, S-methylcysteine sulfoxide is acted upon by alliinase and lachrymatory-factor synthase. S-Methylcysteine sulfoxide is produced from glutathione. Related compounds are the unsaturated sulfoxides S-trans-prop-1-enyl cysteine sulfoxide and S-propyl cysteine sulfoxide, both found also in onions, and S-allyl cysteine sulfoxide, typically found in garlic.
Sources: en.wikipedia.org
Cone snails have a large variety of shell colors and patterns, with local varieties and color forms of the same species often occurring. This variety in color and pattern has led to the creation of a large number of known synonyms and probable synonyms, making it difficult to give an exact taxonomic assignment for many snails in this genus. As of 2009, more than 3,200 different species names have been assigned, with an average of 16 new species names introduced each year. The shells of cone snails vary in size and are conical in shape. The shell is whorled in the form of an inverted cone, with the anterior end being narrower. The protruding parts of the top of the whorls, that form the spire, are in the shape of another more flattened cone. The aperture is elongated and narrow with the sharp operculum being very small. The outer lip is simple, thin, and sharp, without a callus, and has a notched tip at the upper part. The columella is straight. The larger species of cone snails can grow up to 23 cm (9.1 in) in length. The shells of cone snails are often brightly colored with a variety of patterns. Some species color patterns may be partially or completely hidden under an opaque layer of periostracum. In other species, the topmost shell layer is a thin periostracum that is a transparent yellowish or brownish membrane.
=== Availability/affordability === Infliximab is supplied as a sterile, white, lyophilized (freeze-dried) powder, so must be reconstituted and administered by a health care professional, usually in a hospital or office setting. For this reason, it is usually covered under major medical insurance rather than prescription drug coverage. The loading regimen for all approved indications occurs at weeks 0, 2, and 6 at the above dosages. In the UK, infliximab is available from the NHS for Crohn's disease treatment provided three criteria are met. Patients should have severe active Crohn's disease with a CDAI score of 300 or more, have not responded to immunomodulating drugs and corticosteroids, and for whom surgery is inappropriate. Since February 2015, it is also approved for the treatment of ulcerative colitis where other treatments have not worked. In Australia, infliximab is available through the PBS for Crohn's disease treatment provided the patient has not responded to conventional treatment and has a severe case of the condition. Johnson & Johnson reported in its 2013 annual report, "Remicade (infliximab), accounted for approximately 9.4% of the Company's total revenues for fiscal 2013." A self-injectable, subcutaneous version of infliximab, Zymfentra, was approved for medical use in the United States in October 2023.
Since 1975, after the proposal by then Minister for Home Affairs Chua Sian Chin, the death penalty was mandated as the sole punishment for drug trafficking, should the amount of whichever drugs exceed the capital threshold. As a result of this legal reform, 28-year-old Penang-born Malaysian Teh Sin Tong became the first convicted drug trafficker to be hanged at Changi Prison on 28 April 1978, after the High Court found him guilty on 13 October 1976 (a year after the new laws took effect) for trafficking 254.7g of diamorphine across the Woodlands Checkpoint just six months prior to his sentencing. Under Schedule 2 of the Misuse of Drugs Act, any person importing or exporting more than the following quantities of drugs receives a mandatory death sentence:
Sources: en.wikipedia.org
=== Cancer === Specific SNPs are associated with an elevated risk of lung cancer and interact with folate dietary intake in this etiology. The (MTRR):c.66A>G mutation relates to a significant increase in the risk of lung cancer. When co-expressed with the polymorphism (MTR): 2756A>G, lung cancer risk is further increased in a dose dependent manner. Correlation between this polymorphism and increased risk of lung cancer is present with low folate intake and high vitamin B12, suggesting a B12 independent mechanism of action. This mutation is also associated with an increased risk in colorectal cancer, acute lymphoblastic leukemia, bladder cancer, cervical intraepithelial neoplasia, non-Hodgkin lymphoma and esophageal squamous cell carcinoma.
SDS-PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis) is a discontinuous electrophoretic system developed by Ulrich K. Laemmli which is commonly used as a method to separate proteins with molecular masses between 5 and 250 kDa. The combined use of sodium dodecyl sulfate (SDS, also known as sodium lauryl sulfate) and polyacrylamide gel eliminates the influence of structure and charge, and proteins are separated by differences in their size. As of 2025, the publication describing it was the most frequently cited paper by a single author, and the second most cited overall - with over 259,000 citations.
== Advantages == Ionization of the substrate is very efficient as it occurs at atmospheric pressure, and thus has a high collision frequency. Additionally, APCI considerably reduces the thermal decomposition of the analyte because of the rapid desolvation and vaporization of the droplets in the initial stages of the ionization. This combination of factors most typically results in the production of ions of the molecular species with fewer fragmentations than many other ionization methods, making it a soft ionization method. Another advantage to using APCI over other ionization methods is that it allows for the high flow rates typical of standard bore HPLC (0.2–2.0 mL/min) to be used directly, often without diverting the larger fraction of volume to waste. Additionally, APCI can often be performed in a modified ESI source. The ionization occurs in the gas phase, unlike ESI, where the ionization occurs in the liquid phase. A potential advantage of APCI is that it is possible to use a nonpolar solvent as a mobile phase solution, instead of a polar solvent, because the solvent and molecules of interest are converted to a gaseous state before reaching the corona discharge needle. Because APCI involves a gas-phase chemistry, there is no need to use special conditions such as solvents, conductivity, pH for LC. APCI appears to be more versatile LC/MS interface and more compatible with reversed-phase LC than ESI.
== History == Sucrose esters were first mentioned in 1880 by Herzfeld who described the preparation of sucrose octaacetate. The substance is still in use today as a food additive. In 1921, Hess and Messner synthesized sucrose octapalmitate and sucrose octastearate. Both are sucrose fatty acid esters. Rosenthal, in 1924, synthesized highly substituted sucrose fatty acid esters using the classical condensation reaction between sucrose and the acid chloride of the drying oil fatty acid; pyridine was used as a solvent. Rheineck, Rabin, and Long followed the same procedure using alternative polyhydroxyl molecules such as mannitol. These condensation gave low yields, and the products, which were dark in color, needed extensive purification. Moreover, pyridine is a toxic solvent, so the synthesis was not commercially successful. In 1939, Cantor, who patented a production route of sucrose fatty acid esters from starch factory by-products, claimed that the products could be used as emulsifying agents or fats. The classical esterification was used with a mixture of pyridine and either chloroform or carbon tetrachloride as a solvent. Later, the concept of synthesizing sucrose esters from sucrose and fatty acids was patented in 1952. The new synthesis pathway, which involved transesterification of triglycerides and sucrose in the new solvent dimethylformamide, or DMF, was invented and seemed promising.
Sources: en.wikipedia.org
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.
A fatty acid side chain attaches the peptide to serum albumin, which shields it from kidney filtration and protease activity. This interaction is the main reason its circulation time is extended.
No. The native hormone is GLP-1, and semaglutide is an engineered variant with three deliberate structural alterations. It does not appear in unmodified biological sources.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.